An observational study in Laboratory Confirmed SARS-CoV-2 Infection Without Symptoms, sponsored by Prof. Ayola Akim ADEGNIKA. Recruiting at 1 site in Gabon. Open to participants aged 1 Year and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-22.
Sponsored by Prof. Ayola Akim ADEGNIKA · Observational
Gabon is the 3rd country most affected by COVID-19 behind Cameroon and Democratic Republic of Congo in Central Africa, with 8860 cases and 54 deaths in critically ill patients, since the first confirmed case of COVID-19 on the 10th of March 2020 (https://africacdc.org/covid-19/). Most of the individuals infected by SARS-CoV-2 are asymptomatic and they represent a major source of viral spread. To date, African countries have been less affected by deaths caused by the Covid-19 pandemic compared to other countries. It is currently unknown why Africa has avoided more deaths and appears to not simply be due to a lack of testing, since the overall death rate has not increased. Better quality data on seroprevalence in different African regions and proven explanations of the differences between Africa and other continents, are urgently needed. The aim of this study is to learn about the proportion of people after a first pic of transmission, who have been exposed to COVID-19 in Gabon by testing for plasma antibodies to the SARS-CoV-2 virus.
The overall goal of this study is to examine the trend of specific anti-SARS-CoV-2 antibodies in Gabonese population.
Based on its technical capacities (ELISA bench and multiparametric flow cytometer), we will provide evident data on the immune responses in Covid-19 infected patients. The quantification of antibodies against SARS-CoV-2 recombinant protein will be done by ELISA using Wantai ELISA total Ab. Meanwhile, data on clinical status will be recorded and classified using WHO patient form. Data obtained will be analyzed by a statistician based at CERMEL using robust models in compliance with the type of data generated.
A total of 3455 people living in Gabon, aged from 1 year, and above will be stratified by age and included in this study
Exclusion Criteria:
\[1-15\[
Diagnostic Test: Wantai kit Elisa
\[15- 30\[
Diagnostic Test: Wantai kit Elisa
\[30-45\[
Diagnostic Test: Wantai kit Elisa
\[45-60\[
Diagnostic Test: Wantai kit Elisa
60+
Diagnostic Test: Wantai kit Elisa
to mesure antibodies against SARSCov-2 recombinant antigen
seroprevelence on SARS-Cov- 2 infection in Gabon
assess the specific anti-SARS-CoV-2 antibodies in individuals and for modeling the evolution of the COVID-19 outbreak.
Time frame: 4 Months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.